Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17460537 | 0.76 | FFAR4 (0.40) | CA1CA2MKNK1MKNK2PDE3B | |
| SCHEMBL17460472 | 0.76 | FFAR4 (0.42) | ERN1CA1CA2MKNK1MKNK2 | |
| SCHEMBL23073924 | 0.70 | ERN1 (0.39) | ERN1MKNK1MKNK2CYP2A6CD274 | |
| SCHEMBL6213489 | 0.67 | MKNK1 (0.57) | ERN1MKNK1MKNK2CYP2A6PIK3CA | |
| SCHEMBL31174412 | 0.67 | CYP2A6 (0.68) | ERN1CA1CA2MKNK1MKNK2 | |
| SCHEMBL3754419 | 0.67 | CYP2A6 (0.68) | ERN1CA1CA2MKNK1MKNK2 | |
| SCHEMBL677803 | 0.66 | CYP2A6 (0.44) | ERN1CA1CA2MKNK1MKNK2 | |
| SCHEMBL13568538 | 0.64 | CYP11B1 (0.50) | ERN1MKNK1MKNK2CYP2A6HSD17B1 | |
| SCHEMBL19127090 | 0.63 | ERN1 (0.57) | ERN1MKNK1MKNK2CYP2A6HSD17B1 | |
| SCHEMBL3102009 | 0.63 | ERN1 (0.53) | ERN1CA1CA2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172185-B1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | PIRAMAL ENTPR LTD (IN) | 2020-03-04 | — | — | EP | disclosed |
| US-10273230-B2 | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | Piramal Enterprises Limited (IN) | 2019-04-30 | — | — | US | disclosed |
| US-20170210731-A1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-07-27 | — | — | US | disclosed |
| EP-3172185-A2 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012965-A2 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210731-A1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | FFAR1, FFAR3, GPR55 | ERN1 3599/4885CA1 4113/4885CA2 1800/4885 |
| US-10273230-B2 | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | FFAR1, FFAR3, GPR55 | ERN1 3599/4885CA1 4113/4885CA2 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.